169 related articles for article (PubMed ID: 35439284)
1. Evaluation of β-lactam therapeutic drug monitoring among US health systems with postgraduate year 2 infectious diseases pharmacy residency programs.
Chen C; Seabury RW; Steele JM; Parsels KA; Darko W; Miller CD; Kufel WD
Am J Health Syst Pharm; 2022 Jul; 79(15):1273-1280. PubMed ID: 35439284
[TBL] [Abstract][Full Text] [Related]
2. Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study.
Ewoldt TMJ; Abdulla A; van den Broek P; Hunfeld N; Bahmany S; Muller AE; Gommers D; Polinder S; Endeman H; Spronk I; Koch BCP
BMC Infect Dis; 2022 Jul; 22(1):611. PubMed ID: 35831793
[TBL] [Abstract][Full Text] [Related]
3. Barriers and Facilitators in the Clinical Implementation of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: A Critical Review.
Abdulla A; van den Broek P; Ewoldt TMJ; Muller AE; Endeman H; Koch BCP
Ther Drug Monit; 2022 Feb; 44(1):112-120. PubMed ID: 34798631
[TBL] [Abstract][Full Text] [Related]
4. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units.
Wong G; Brinkman A; Benefield RJ; Carlier M; De Waele JJ; El Helali N; Frey O; Harbarth S; Huttner A; McWhinney B; Misset B; Pea F; Preisenberger J; Roberts MS; Robertson TA; Roehr A; Sime FB; Taccone FS; Ungerer JP; Lipman J; Roberts JA
J Antimicrob Chemother; 2014 May; 69(5):1416-23. PubMed ID: 24443514
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation.
Sandaradura I; Alffenaar JW; Cotta MO; Daveson K; Day RO; Van Hal S; Lau C; Marriott DJE; Penm J; Roberts JA; Tabah A; Williams P; Imani S
Br J Clin Pharmacol; 2022 Feb; 88(2):669-679. PubMed ID: 34289135
[TBL] [Abstract][Full Text] [Related]
6. A guide to therapeutic drug monitoring of β-lactam antibiotics.
Fratoni AJ; Nicolau DP; Kuti JL
Pharmacotherapy; 2021 Feb; 41(2):220-233. PubMed ID: 33480024
[TBL] [Abstract][Full Text] [Related]
7. Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study.
Barreto EF; Rule AD; Alshaer MH; Roberts JA; Abdul Aziz MH; Scheetz MH; Mara KC; Jannetto PJ; Gajic O; O'Horo JC; Boehmer KR
Implement Sci Commun; 2021 Mar; 2(1):34. PubMed ID: 33762025
[TBL] [Abstract][Full Text] [Related]
8. National survey of pharmacy residency on-call programs.
Holder M; Smith KM; Fugit A; Macaulay T; Cook AM
Am J Health Syst Pharm; 2013 Oct; 70(19):1676-80. PubMed ID: 24048604
[TBL] [Abstract][Full Text] [Related]
9. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France.
Charmillon A; Novy E; Agrinier N; Leone M; Kimmoun A; Levy B; Demoré B; Dellamonica J; Pulcini C
Clin Microbiol Infect; 2016 Jul; 22(7):625-31. PubMed ID: 27145210
[TBL] [Abstract][Full Text] [Related]
10. Implementation Strategies Addressing Stakeholder-Perceived Barriers and Enablers to the Establishment of a Beta-Lactam Antibiotic Therapeutic Drug Monitoring Program: A Qualitative Analysis.
Pai Mangalore R; Udy AA; Peel TN; Peleg AY; Ayton D
Ther Drug Monit; 2024 Jun; 46(3):351-362. PubMed ID: 38018820
[TBL] [Abstract][Full Text] [Related]
11. Selecting candidates for pharmacy residencies: A national survey of residency program directors.
Cho JC
J Clin Pharm Ther; 2018 Dec; 43(6):844-848. PubMed ID: 29902326
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Postgraduate Year 2 Pharmacy Residency Programs Within the Veterans Affairs Healthcare System.
Naples JG; Mantovani EH; Rothrock-Christian T; Brown JN
J Pharm Pract; 2017 Apr; 30(2):180-184. PubMed ID: 26801656
[TBL] [Abstract][Full Text] [Related]
13. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
[TBL] [Abstract][Full Text] [Related]
14. Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.
Venugopalan V; Hamza M; Santevecchi B; DeSear K; Cherabuddi K; Peloquin CA; Alshaer MH
Am J Health Syst Pharm; 2022 Sep; 79(18):1586-1591. PubMed ID: 35704702
[TBL] [Abstract][Full Text] [Related]
15. Assessment of current practice for β-lactam therapeutic drug monitoring in French ICUs in 2021: a nationwide cross-sectional survey.
Tritscher P; Delannoy M; Agrinier N; Charmillon A; Degand N; Dellamonica J; Roger C; Leone M; Scala-Bertola J; Novy E
J Antimicrob Chemother; 2022 Sep; 77(10):2650-2657. PubMed ID: 36059108
[TBL] [Abstract][Full Text] [Related]
16. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
[TBL] [Abstract][Full Text] [Related]
17. Why is the Implementation of Beta-Lactam Therapeutic Drug Monitoring for the Critically Ill Falling Short? A Multicenter Mixed-Methods Study.
Barreto EF; Chitre PN; Pine KH; Shepel KK; Rule AD; Alshaer MH; Abdul Aziz MH; Roberts JA; Scheetz MH; Ausman SE; Moreland-Head LN; Rivera CG; Jannetto PJ; Mara KC; Boehmer KR
Ther Drug Monit; 2023 Aug; 45(4):508-518. PubMed ID: 37076424
[TBL] [Abstract][Full Text] [Related]
18. Survey of residency program directors' perceptions of nontraditional pharmacy residency applicants.
Khalil AJ; Mediwala KN; Mehta M; Yanicak AJ; Ham JS; Blake EW; Rumley KF; Pan I; Bookstaver PB
Am J Health Syst Pharm; 2019 Oct; 76(21):1788-1793. PubMed ID: 31612922
[TBL] [Abstract][Full Text] [Related]
19. Postgraduate year 1 pharmacy residency director perceptions of elective courses about residency training.
Johnson C; Boehmer K
Curr Pharm Teach Learn; 2021 Jan; 13(1):1-4. PubMed ID: 33131611
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of postgraduate year 2 ambulatory care pharmacy residency programs in the United States.
Musch KLE; Schreck TE; Casper KA; Rodis JL
Am J Health Syst Pharm; 2020 May; 77(Supplement_2):S34-S40. PubMed ID: 32426832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
